A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

NCT00054834 Phase 1 TERMINATED

The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.

Details

Lead sponsor	Gilead Sciences
Phase	Phase 1
Status	TERMINATED
Enrolment	27
Start date	2003-03

Conditions

• Non-Hodgkins Lymphoma

Interventions

• hLL2 (epratuzumab)

Countries

United States